LAVA Therapeutics NV is a biotechnology business based in the US. LAVA Therapeutics shares (LVTX) are listed on the NASDAQ and all prices are listed in US Dollars. LAVA Therapeutics employs 55 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $3.16 |
|---|---|
| 52-week range | $2.28 - $11.13 |
| 50-day moving average | $3.28 |
| 200-day moving average | $5.10 |
| Wall St. target price | $22.41 |
| PE ratio | 0.3223 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $9.79 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.155 from 2022-07-01
| 1 week (2022-06-28) | 8.79% |
|---|---|
| 1 month (2022-06-03) | 2.10% |
| 3 months (2022-04-05) | -27.47% |
| 6 months (2022-01-05) | -45.42% |
| 1 year (2021-07-02) | -70.92% |
|---|---|
| 2 years (2020-07-01) | N/A |
| 3 years (2019-07-01) | N/A |
| 5 years (2017-07-01) | N/A |
Valuing LAVA Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of LAVA Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
LAVA Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, LAVA Therapeutics shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, LAVA Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
| Revenue TTM | $5 million |
|---|---|
| Gross profit TTM | $-32,193,000 |
| Return on assets TTM | -15.38% |
| Return on equity TTM | -29.94% |
| Profit margin | 0% |
| Book value | $4.21 |
| Market capitalisation | $81.3 million |
TTM: trailing 12 months
We're not expecting LAVA Therapeutics to pay a dividend over the next 12 months.
LAVA Therapeutics N. V. , a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.